ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Director, Insights and Analytics at Dyne Therapeutics - ApplyBlast

Director, Insights and Analytics

Dyne Therapeutics

4 months ago

4.1 on Glassdoor

Waltham, MA

Onsite

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Director, Insights and Analytics at Dyne Therapeutics leads the generation of market, customer, and data-driven insights to shape commercial strategy for rare neuromuscular diseases. This role integrates forecasting, competitive intelligence, and advanced analytics to inform strategic decisions and optimize go-to-market planning for clinical pipeline assets.

Responsibilities

Lead development of global forecasting models and scenario planning tools
Design and execute comprehensive market research plans and strategies
Oversee competitive intelligence activities and analysis for therapeutic areas
Develop dashboards and KPIs to enable data-driven decision-making
Serve as strategic advisor to cross-functional stakeholders on commercial strategy

Skills

Qualifications

MBAPhDPharmD

About Dyne Therapeutics

dyne-tx.com

Headquarters

Waltham, Massachusetts, United States

Company Size

51-200 employees

Founded

2018

View Profile

Dyne Therapeutics is a biotechnology company developing nucleic acid–based therapies for genetically driven neuromuscular diseases. Leveraging its proprietary FORCE™ platform, Dyne aims to address the root cause of disease and deliver functional improvement for people living with conditions such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). The company advances a pipeline of therapeutics from discovery through clinical development with the mission of transforming the lives of patients with rare neuromuscular diseases.